S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
With oil prices slumping, OPEC+ producers weigh more production cuts
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Slow start to New York's legal pot market leaves farmers holding the bag
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
With oil prices slumping, OPEC+ producers weigh more production cuts
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Slow start to New York's legal pot market leaves farmers holding the bag
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
With oil prices slumping, OPEC+ producers weigh more production cuts
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Slow start to New York's legal pot market leaves farmers holding the bag
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
With oil prices slumping, OPEC+ producers weigh more production cuts
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Slow start to New York's legal pot market leaves farmers holding the bag
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
NASDAQ:CARA

Cara Therapeutics (CARA) Earnings Date, Estimates & Call Transcripts

$3.09
0.00 (0.00%)
(As of 06/2/2023 ET)
Compare
Today's Range
$2.99
▼
$3.24
50-Day Range
$3.09
▼
$5.08
52-Week Range
$2.99
▼
$12.98
Volume
1.65 million shs
Average Volume
786,268 shs
Market Capitalization
$166.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.83
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
Aug. 14Estimated
Actual EPS
(Mar. 6)
-$0.56 Missed By -$0.23
Consensus EPS
(Mar. 6)
-$0.33
Last Year's Q1 EPS
(3/1/2022)
-$0.63
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

CARA Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CARA Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Cara Therapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20233($0.54)($0.22)($0.41)
Q2 20233($0.60)($0.11)($0.38)
Q3 20233($0.62)$0.01($0.28)
Q4 20233($0.50)$0.07($0.20)
FY 202312($2.26)($0.25)($1.27)

CARA Earnings Date and Information

Cara Therapeutics last announced its quarterly earnings data on March 6th, 2023. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by $0.23. The firm earned $3.26 million during the quarter, compared to analyst estimates of $14.03 million. Cara Therapeutics has generated ($1.56) earnings per share over the last year (($1.56) diluted earnings per share). Earnings for Cara Therapeutics are expected to grow in the coming year, from ($1.89) to ($0.94) per share. Cara Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 14th, 2023 based off prior year's report dates.

Cara Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/14/2023
(Estimated)		        
3/6/2023Q4 2022($0.33)($0.56)($0.23)($0.56)$14.03 million$3.26 million
11/7/2022Q3 2022($0.42)($0.43)($0.01)($0.43)$8.39 million$10.81 million
8/8/2022Q2 2022($0.28)($0.08)+$0.20($0.08)$21.28 million$23.00 million
5/9/2022Q1 2022($0.56)($0.52)+$0.04($0.52)$15.82 million$4.79 million    
3/1/2022Q4 2021($0.50)($0.63)($0.13)($0.63)$3.62 million$0.82 million    
11/7/20219/30/2021($0.36)($0.02)+$0.34($0.02)$15.74 million$20.27 million    
8/8/20216/30/2021($0.55)($0.61)($0.06)($0.61)    
5/9/20213/31/2021($0.59)($0.47)+$0.12($0.47)$10.15 million$1.94 million  
2/25/202112/31/2020($0.53)$1.59+$2.12$1.59$6.63 million$112.09 million  
11/14/2020Q3($0.60)($0.35)+$0.25($0.35)$4.98 million$9.27 million  
8/10/20206/30/2020($0.68)($0.54)+$0.14($0.54)$5.48 million$5.63 million  
5/11/20203/31/2020($0.63)($0.62)+$0.01($0.62)$4.83 million$8.09 million  
2/27/202012/31/2019($0.66)($0.61)+$0.05($0.61)$5.58 million$4.51 million  
11/5/2019Q3($0.59)($0.74)($0.15)($0.74)$5.56 million$5.79 million  
8/7/2019Q2 2019($0.61)($0.58)+$0.03($0.58)$5.14 million$5.21 million  
5/7/20193/31/2019($0.55)($0.56)($0.01)($0.56)$5.14 million$4.38 million
3/12/201912/31/2018($0.59)($0.52)+$0.07($0.52)$3.35 million$5.53 million  
11/6/2018Q3($0.46)($0.51)($0.05)($0.51)$4.72 million$5.06 million  
8/7/2018Q2 2018($0.50)($0.5160)($0.0160)($0.52)$0.63 million$2.87 million
5/9/2018Q1 2018($0.4740)($0.5130)($0.0390)($0.51)$0.19 million
3/15/2018Q4 2017($0.39)($0.43)($0.04)($0.43)$0.11 million  
11/2/2017Q3 2017($0.35)($0.38)($0.03)($0.38)$0.27 million
8/3/2017Q2 2017($0.61)($0.29)+$0.32($0.29)$0.13 million  
5/4/2017Q1 2017($0.73)($0.81)($0.08)($0.81)$0.11 million$0.91 million  
3/9/2017Q4 2016($0.53)($0.81)($0.28)($0.81)
11/3/2016Q3($0.47)($0.42)+$0.05($0.42)$0.09 million
8/4/2016Q216($0.42)($0.48)($0.06)($0.48)$0.13 million$0.08 million
5/5/2016Q116($0.40)($0.39)+$0.01($0.39)$0.03 million$0.01 million
3/10/2016Q4($0.33)($0.35)($0.02)($0.35)$0.53 million  
11/9/2015Q315($0.27)($0.19)+$0.08($0.19)$1.86 million$2.40 million
8/10/2015Q215($0.24)($0.25)($0.01)($0.25)$0.50 million$0.87 million  
5/12/2015Q415($0.22)($0.21)+$0.01($0.21)$0.70 million$0.50 million  
3/26/2015Q4($0.28)($0.18)+$0.10($0.18)$1.00 million$0.91 million  
11/10/2014Q314($0.22)($0.29)($0.07)($0.29)$0.13 million$1.13 million
8/7/2014Q2($0.27)($0.16)+$0.11($0.16)$0.08 million$0.96 million
5/12/2014Q1($0.14)($0.22)($0.08)($0.22)$0.30 million$0.18 million  
3/27/2014Q4 2013($0.42)($0.49)($0.07)($0.49)$0.90 million$0.97 million












Cara Therapeutics Earnings - Frequently Asked Questions

When is Cara Therapeutics's earnings date?

Cara Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 14th, 2023 based off last year's report dates. Learn more on CARA's earnings history.

Did Cara Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Cara Therapeutics (NASDAQ:CARA) missed the analysts' consensus estimate of ($0.33) by $0.23 with a reported earnings per share (EPS) of ($0.56). Learn more on analysts' earnings estimate vs. CARA's actual earnings.

How much revenue does Cara Therapeutics generate each year?

Cara Therapeutics (NASDAQ:CARA) has a recorded annual revenue of $41.87 million.

How much profit does Cara Therapeutics generate each year?

Cara Therapeutics (NASDAQ:CARA) has a recorded net income of -$85.47 million. CARA has generated -$1.56 earnings per share over the last four quarters.

What is Cara Therapeutics's EPS forecast for next year?

Cara Therapeutics's earnings are expected to grow from ($1.89) per share to ($0.94) per share in the next year.

More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:CARA) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -